Kornitzer Capital Management Inc. KS Sells 8,100 Shares of Cencora, Inc. $COR

Kornitzer Capital Management Inc. KS cut its stake in Cencora, Inc. (NYSE:COR) by 26.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 22,560 shares of the company’s stock after selling 8,100 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Cencora were worth $7,087,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COR. JFS Wealth Advisors LLC boosted its stake in Cencora by 30.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock worth $42,000 after purchasing an additional 29 shares during the period. Apollon Wealth Management LLC boosted its position in shares of Cencora by 0.5% in the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after acquiring an additional 30 shares during the period. Accent Capital Management LLC grew its stake in Cencora by 36.1% during the fourth quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after acquiring an additional 30 shares in the last quarter. MCF Advisors LLC increased its holdings in Cencora by 11.0% during the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock worth $102,000 after acquiring an additional 30 shares during the period. Finally, CYBER HORNET ETFs LLC increased its holdings in Cencora by 6.8% during the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock worth $164,000 after acquiring an additional 31 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on COR. Bank of America raised their price target on shares of Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Citigroup lowered their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Barclays reduced their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Eleven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Price Performance

Cencora stock traded up $0.85 during mid-day trading on Friday, hitting $303.31. 761,459 shares of the company traded hands, compared to its average volume of 1,586,448. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The stock has a market cap of $59.01 billion, a price-to-earnings ratio of 23.26, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. The stock has a fifty day moving average price of $277.22 and a 200-day moving average price of $318.98.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is currently 18.40%.

Cencora declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.38% of the stock is owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.